Abstract
BackgroundThere is a dearth of data on effectiveness and patient reported outcomes in patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) treated with adalimumab (ADA) in Central and Eastern...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
